Isomorphic Labs Raises $2.1 Billion: What It Means for AI Drug Discovery Valuations

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, announced today that it has raised $2.1 billion in a Series B funding round. This brings the company's total capital raised to approximately $2.7 billion, following a $600 million Series A just 14 months ago.

The round was led by Thrive Capital, which also led the first round. Alphabet participated again through both its venture arm GV and growth fund CapitalG. The new investors are notable: Abu Dhabi's MGX, Singapore's Temasek, and the UK Sovereign AI Fund. It is worth pausing on the fact that MGX has also invested in both OpenAI and Anthropic, making it one of a small number of capital allocators with positions across all three major foundation model companies now entering life sciences.

Isomorphic Labs CEO Demis Hassabis, who also leads Google DeepMind, described the round as validation of the company's "AI-first approach to drug design and development." The company now has more than 350 employees across London, Cambridge (Massachusetts), and Lausanne, and maintains partnerships with Eli Lilly, Novartis, and Johnson & Johnson.

$2.7 Billion Raised, No Drug Candidate Disclosed

The most striking thing about this round is the sheer scale of capital flowing into a platform where pre-clinical work is underway but no drug candidate has been publicly disclosed and clinical trials have not begun.

Hassabis predicted last year that Isomorphic would enter clinical trials by the end of 2025. In the Bloomberg interview accompanying today's announcement, he clarified that he "misspoke" and was actually referring to pre-clinical trials, which have now started. Full clinical trials remain on the horizon but have not begun.

This is not unique to Isomorphic. As Bloomberg noted in its reporting, no AI-designed drug has reached the market. The broader landscape shows a field that has attracted enormous capital but is still working to prove its fundamental premise in the clinic. Recursion Pharmaceuticals, one of the earliest public AI drug discovery companies, is down nearly 90% from its 2021 IPO price. BenevolentAI, the British AI drug discovery firm that partnered with AstraZeneca, de-listed last year.

The question is whether this pattern represents a sector still in the "invest before proof" phase of a technology cycle that will eventually deliver, or whether valuations have outpaced biological reality. We do not think anyone can answer that definitively right now, including us.

Why Sovereign Wealth Funds Are Moving In

One of the more notable features of this round is the investor composition. MGX, Temasek, and the UK Sovereign AI Fund are not venture capital firms looking for 10x returns on a three-year timeline. These are patient, long-duration capital allocators making structural bets on entire technology categories.

Their presence in an AI drug discovery round signals something about how this sector is being categorized by the largest pools of capital in the world. It is being treated less as a speculative biotech bet and more as critical AI infrastructure, similar to how sovereign wealth funds have invested in compute, energy, and semiconductor capacity.

This framing matters for valuation. If AI drug discovery companies are being priced as technology infrastructure rather than biotech pipeline risk, the valuation framework shifts significantly. Infrastructure companies trade on the expectation of durable competitive advantage and long-term cash generation, not probability-weighted clinical outcomes.

Whether that framing is correct or premature is an open question. But the fact that the world's largest sovereign capital pools are endorsing it is a meaningful data point.

The Cross-Pollination of Investors

Something we have been tracking across the broader AI-to-life-sciences deal landscape is the degree to which investor bases are overlapping across foundation model companies and their life sciences spinouts.

Thrive Capital led Isomorphic's Series A and Series B. Thrive is also a major backer of OpenAI. MGX, a new investor in Isomorphic, has invested in both OpenAI and Anthropic. This means a single sovereign wealth fund now has financial exposure to the life sciences strategies of all three major foundation model ecosystems simultaneously.

We do not know whether this reflects a deliberate strategy to capture the AI-life-sciences opportunity regardless of which platform wins, or whether it simply reflects the limited number of capital allocators writing checks at this scale. But the overlap is real, and it has implications for how competitive dynamics play out. When your investors are also invested in your competitors, the incentives around collaboration versus competition become more complex.

What This Means for AI Drug Discovery Valuations

Isomorphic has not disclosed its valuation, but some rough math is instructive. Total capital raised is approximately $2.7 billion. If we assume Thrive and other investors secured meaningful ownership in the first round and the Series B came at a higher price (which is typical for a 250%+ step-up in round size), a post-money valuation somewhere in the range of $10 billion to $15 billion would not be unreasonable, though this is our estimate, not a disclosed figure.

For context, here is how this compares to other recent transactions in the space:

Recursion Pharmaceuticals, a public company with more than 10 clinical programs and $450 million in realized partner payments, has a market capitalization that has fluctuated but currently sits well below $5 billion. Recursion also acquired Exscientia for approximately $688 million in November 2024.

Valo Health, which has a partnership with Novo Nordisk worth up to $4.6 billion in milestones, has not disclosed a standalone valuation.

Insilico Medicine, which signed a deal with Eli Lilly worth up to $2.75 billion, remains private.

Earendil Labs raised $787 million in March 2026 with a Phase 2-ready lead asset and 40+ programs.

What seems clear is that Isomorphic occupies a unique position at the top of the AI drug discovery valuation stack, driven by a combination of the AlphaFold lineage, the pharma partnership portfolio (Lilly, Novartis, J&J), and the implicit backing of Alphabet. Whether that position is justified will ultimately depend on clinical data that does not yet exist.

The Broader Pattern

We have been tracking more than 50 transactions at the intersection of AI and life sciences over the past eight years, totaling more than $90 billion in disclosed deal value. Several patterns have emerged.

First, deal velocity is accelerating. In the past 18 months alone, Anthropic acquired Coefficient Bio for approximately $400 million, OpenAI acquired Torch Health for approximately $100 million, Eli Lilly signed a $2.75 billion deal with Insilico Medicine, Novo Nordisk expanded its Valo Health partnership to $4.6 billion, Nvidia launched a $1 billion co-innovation lab with Lilly, and now Isomorphic has raised $2.1 billion. Capital is entering the space faster than clinical data can validate it.

Second, there appear to be two distinct buying motions happening simultaneously. Foundation model companies and their spinouts (Anthropic, OpenAI, Isomorphic Labs) are making investments and acquisitions where the pricing does not correspond to traditional revenue or EBITDA metrics. Pharma companies (Lilly, Novo Nordisk, Novartis) are structuring milestone-heavy partnerships that tie payments to specific clinical and therapeutic outcomes. The valuation logic in each case is fundamentally different.

Third, the investor base is converging. Sovereign wealth funds, Big Tech corporate venture, and top-tier VC firms are all circling the same small number of AI drug discovery platforms. This concentration of capital at the top may leave mid-market AI-bio companies in an increasingly difficult position: too small for sovereign wealth fund allocations, too undifferentiated for foundation model acqui-hires, and too early for milestone-heavy pharma partnerships.

What We Are Watching

Isomorphic's clinical timeline is now the single most consequential data point for the entire AI drug discovery sector. If AI-designed drugs enter and succeed in human trials within the next two years, the current valuations will look prescient. If they do not, the $90 billion in capital deployed across this space will face a reckoning similar to what Recursion and BenevolentAI have already experienced.

Hassabis told Bloomberg that a full spinout from Alphabet is "definitely one of the options." If that happens, it would create the first standalone, publicly traded, pure-play AI drug discovery company with this kind of capital base and partnership portfolio. That event, and its pricing, would set the benchmark for the entire sector.

We will continue to track and publish our analysis of deals across this space. Our interactive network chart mapping all 50+ transactions and their relationships is available on our [resources page](/resources/life-sciences-network).

MaTrx.ai is an AI-native investment banking firm focused on technology and life sciences M&A advisory. For more information, visit [matrx.ai](https://matrx.ai).